



Making Science work for you...

Jubilant Organosys Ltd.

Regd.Off: Bhartiagram, Gajraula, Distt. Jyotiba Phoolay Nagar - 244 223 (U.P.)

FY 2008

Net Sales up
38%

EBIDTA up
60%

PAT up
76%

Audited Financial Results for the Year ended 31st March, 2008

(Rs. in Million)

(Rs. in Million)

CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
9 Months Ended Dec. 31 (Unaudited)	Quarter Ended March 31 (Unaudited)	Year Ended March 31 (Audited)	2007	2008		9 Months Ended Dec. 31 (Unaudited)	Quarter Ended March 31 (Unaudited)	Year Ended March 31 (Audited)	2007	2008
2007	2008	2007	2008	2007		2007	2008	2007	2008	2007
17999	6890	4633	24889	18097	Net sales/Income from operations	14424	5343	4296	19767	16097
1612	(182)	631	1430	1234	Other income	1378	(230)	522	1148	968
19611	6708	5264	26319	19331	Total income	15802	5113	4818	20915	17065
15286	6005	4444	21291	16151	Total expenditure	11653	4387	3963	16040	13902
(56)	(98)	8	(154)	(253)	a) (Increase)/Decrease in stock in trade and work in progress	(69)	(93)	81	(162)	(197)
351	156	81	507	396	b) Purchase of traded goods	333	142	98	475	370
6860	2650	2110	9510	8160	c) Raw & process materials consumed	6465	2478	2098	8943	7916
1220	454	338	1674	1133	d) Stores, spares, chemicals, catalyst & packing material consumed	813	254	267	1067	961
1197	507	343	1704	1305	e) Power & fuel	1153	488	336	1641	1298
422	171	152	593	533	f) Other manufacturing expenses	387	145	145	532	512
2756	1083	552	3839	2149	g) Staff cost	987	306	271	1293	975
678	361	166	1039	623	h) Depreciation	429	207	132	636	516
1858	721	694	2579	2105	i) Selling, general & admin. expenses	1155	460	535	1615	1551
4325	703	820	5028	3180	Operating profit before interest	4149	726	855	4875	3163
316	21	54	337	195	Interest (Net)	169	(22)	46	147	151
36	93	16	129	32	Exceptional items	36	93	16	129	16
3973	589	750	4562	2953	Profit from Ordinary Activities before tax	3944	655	793	4599	2996
593	(20)	122	573	712	Tax Expenses (Net)	592	84	97	676	681
3380	609	628	3989	2241	Net profit from Ordinary Activities after tax	3352	571	696	3923	2315
-	-	-	-	-	Extraordinary Items (net of tax expenses)	-	-	-	-	-
(43)	27	(10)	(16)	(39)	Minority Interest	-	-	-	-	-
3423	582	638	4005	2280	Net profit after Minority Interest	3352	571	696	3923	2315
144.1	146.2	143.5	146.2	143.5	Paid-up share capital (Face value per share Re.1)	144.1	146.2	143.5	146.2	143.5
			12415	8918	Reserves (excluding revaluation reserve)				13640	9473
23.85	4.01	4.44	27.83	15.93	Basic (Rs.)	23.35	3.94	4.85	27.26	16.17
19.18	3.22	3.59	22.42	13.02	Diluted (Rs.)	18.78	3.16	3.91	21.96	13.22
69728523	71807890	69067310	71807890	69067310	Public shareholding	69728523	71807890	69067310	71807890	69067310
48.39	49.12	48.15	49.12	48.15	- Number of shares (Re 1 each)	48.39	49.12	48.15	49.12	48.15
					- Percentage of shareholding					

Notes:

- The Board of Directors in the meeting held on 4th April, 2008, has approved acquisition of Draxis Health Inc., a premier specialty pharmaceutical company in Canada which offers Contract Manufacturing services in the area of sterile and non-sterile products and also focuses on discovering, developing and manufacturing diagnostic imaging and therapeutic radiopharmaceutical products at a price of USD \$6 per share in cash by way of plan of arrangement. The total value of the transaction is approx. USD \$ 255 million and is likely to be complete by Q1-FY2009. The transaction is subject to customary closing conditions and necessary requisite regulatory approvals.
- During the quarter, the company increased its holding in its subsidiary Jubilant First Trust Healthcare Ltd. from 84.36% to 88.17%.
- The company through its subsidiary Jubilant First Trust Healthcare Ltd acquired 99.68% stake in Asia Healthcare Development Pvt Ltd (AHDPL) for Rs.12.52 million. The AHDPL is engaged in the business of Development & Management of Hospitals & Health Care units.
- During the quarter, the Paid-up Equity Share Capital increased to Rs.146.2 million, upon allotment of 40,500 equity shares on exercise of vested options under the Employee Stock Option Scheme Plan - 2005 and allotment of 2,038,867 equity shares on conversion of FCCB's.

Segment Wise Revenue, Results & Capital Employed (Under Clause 41 of the Listing Agreement)										
CONSOLIDATED RESULTS					Particulars	JUBILANT ORGANOSYS LTD.				
9 Months Ended Dec. 31 (Unaudited)	Quarter Ended March 31 (Unaudited)	Year Ended March 31 (Audited)	2007	2008		9 Months Ended Dec. 31 (Unaudited)	Quarter Ended March 31 (Unaudited)	Year Ended March 31 (Audited)	2007	2008
2007	2008	2007	2008	2007		2007	2008	2007	2008	2007
10693	4609	2277	15302	8950	Segment revenue	7144	3062	1926	10206	6940
7329	2299	2363	9628	9175	a. Pharmaceuticals and Life Science Products & Services	7144	3062	1926	10206	6940
18022	6908	4640	24930	18125	Total	14447	5361	4303	19808	16125
23	18	7	41	28	Less : Inter segment revenue	23	18	7	41	28
17999	6890	4633	24889	18097	Net sales/Income from operations	14424	5343	4296	19767	16097
10693	4609	2277	15302	8950	a. Pharmaceuticals and Life Science Products & Services	7144	3062	1926	10206	6940
7306	2281	2356	9587	9147	b. Industrial & Performance Products	7280	2281	2370	9561	9157
17999	6890	4633	24889	18097	Total	14424	5343	4296	19767	16097
2295	807	466	3102	1765	Segment results (profit+)/loss(-) before tax and interest from each segment	2320	877	617	3197	1980
1169	155	281	1324	1065	a. Pharmaceuticals and Life Science Products & Services	2320	877	617	3197	1980
3464	962	747	4426	2830	Total	3492	1032	899	4524	3049
316	21	54	337	195	Less : i Interest	169	(22)	46	147	151
505	230	230	735	475	ii. Other un-allocable expenditure	504	229	230	733	459
(1330)	122	(287)	(1208)	(793)	iii. Un-allocable Income	(1125)	170	(170)	(955)	(557)
3973	589	750	4562	2953	Total profit before tax	3944	655	793	4599	2996
22649	23773	13891	23773	13891	Capital Employed (Segment assets less Segment liabilities)	10647	11283	8960	11283	8960
5797	6814	5723	6814	5723	a. Pharmaceuticals and Life Science Products & Services	10647	11283	8960	11283	8960
28446	30587	19614	30587	19614	Total Capital employed in segments	16440	18097	14656	18097	14656
4482	4576	7508	4576	7508	Add: Un-allocable corporate assets less liabilities	13574	13772	12273	13772	12273
32928	35163	27122	35163	27122	Total capital employed in the Company	30014	31869	26929	31869	26929

- Other Income includes exchange loss of Rs.261 million for Q4-FY 2008(previous year-Q4-FY 2007 gain of Rs.458 million) and for the FY 2008 aggregate net gain of Rs.1040 million (previous year FY 2007 of Rs.658 million) on foreign currency borrowings including Foreign Currency Convertible Bonds.
- Effective 1st April 2007, the company adopted the revised Accounting Standard (AS-15) on Employee benefits. Pursuant to adoption, the provisions applicable to transitional period, additional liability upto 31st March, 2007, amounting to Rs.90.23 million has been adjusted from General Reserve (net of deferred tax Rs.46.47 million)
- The Board has recommended a dividend of Rs.1.50 per equity share of Re.1 totaling to Rs.256.55 million, subject to approval in Annual General Meeting
- Figures for previous period / year have been regrouped / reclassified / restated, wherever considered necessary.
- Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New -52, Disposals -52, Closing Balance - Nil.
- The above Financial Results were reviewed by the Audit Committee and were taken on record by the Board of Directors at its meeting held on 22nd April, 2008.

For Jubilant Organosys Ltd.

Place : Noida
Dated : 22nd April, 2008

Shyam S Bhartia
Chairman & Managing Director

visit us at www.jubl.com

33x28 sq.cm.